Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug (NSAID)
Acetaminophen + Ibuprofen for Patent Ductus Arteriosus in Extremely Premature Infants
Phase 2
Recruiting
Led By Amish Jain, MD PhD
Research Sponsored by Mount Sinai Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Preterm infants born <27+0 weeks gestational age
Diagnosis of PDA ≥ 1.5 mm on echocardiography with unrestrictive predominantly left to right shunt
Must not have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up6-10 days post treatment initiation
Awards & highlights
Study Summary
This trial is testing whether a combination of ibuprofen and acetaminophen is more effective than ibuprofen alone in treating patent ductus arteriosus, a common heart problem in premature babies.
Eligible Conditions
- Patent Ductus Arteriosus
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
Babies born before 27 weeks of pregnancy.
Select...
You have a certain type of heart problem called a PDA that is larger than 1.5 millimeters and is causing a specific type of blood flow in the heart.
Select...
You are scheduled to receive your first treatment with ibuprofen through a vein or through your stomach, as decided by your medical team.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6-10 days post treatment initiation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-10 days post treatment initiation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Composite of pre-discharge mortality or any grade BPD
Secondary outcome measures
Duration (days) of invasive or non-invasive respiratory support
Further exposure to pharmacological PDA treatments
Mortality
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Combination TherapyExperimental Treatment2 Interventions
Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And study drug (intravenous acetaminophen 15 mg/kg/dose IV q6h for 3 days).
Group II: Standard Clinical Practice - MonotherapyPlacebo Group2 Interventions
Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And Placebo [(0.9% saline IV q6h for 3 days).
Find a Location
Who is running the clinical trial?
Mount Sinai Hospital, CanadaLead Sponsor
193 Previous Clinical Trials
67,048 Total Patients Enrolled
Sunnybrook Health Sciences CentreOTHER
636 Previous Clinical Trials
1,477,862 Total Patients Enrolled
McMaster Children's HospitalOTHER
38 Previous Clinical Trials
17,118 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have not been treated with any medication for a certain condition called PDA, except for using indomethacin to prevent bleeding in the brain.Babies born before 27 weeks of pregnancy.Abnormalities in the chromosomesYou have a certain type of heart problem called a PDA that is larger than 1.5 millimeters and is causing a specific type of blood flow in the heart.You are scheduled to receive your first treatment with ibuprofen through a vein or through your stomach, as decided by your medical team.You have fewer than 50,000 platelets in a small amount of blood.Your kidneys are not working well, as shown by low urine output or high levels of creatinine in your blood.Your liver function is not normal, with high levels of ALT in your blood.
Research Study Groups:
This trial has the following groups:- Group 1: Combination Therapy
- Group 2: Standard Clinical Practice - Monotherapy
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an open opportunity for patients to enroll in this research?
"The information on clinicaltrials.gov reveals that this medical trial is not currently recruiting, even though it was initially posted November 1st 2022 and most recently updated October 24th 2022. Nevertheless, there are over two hundred sixty-nine other studies open for enrollment at present."
Answered by AI
Does the FDA recognize Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen) as safe for use?
"Our evaluation yielded a score of 2 for the safety profile of Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen). This is due to Phase 2 trial data, which indicates that while there are some preliminary studies showing safety, no efficacy has been demonstrated."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger